Cutaneous melanoma · line 4 · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	4
Track	palliative
Linked regimen	`None`

ID	`IND-MELANOMA-3L-POST-LIFILEUCEL`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-MELANOMA`
Sources	`SRC-ESMO-MELANOMA-2024` `SRC-NCCN-MELANOMA-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. 4L+ palliative pathway after exhaustion of all current active therapies (ICI, BRAF/MEK, TIL). Trial enrollment + palliative care + hospice referral are the primary considerations.

Used By

Indication

IND-MELANOMA-NIVO-MAINT - IND-MELANOMA-NIVO-MAINT